Research
Hormonal
In the 10-mg tirzepatide group, 56% of participants achieved resolution of MASH without worsening of fibrosis compared to 10% in the placebo group (difference of 46 percentage points; P<0.001).
Tirzepatide may be an effective treatment option for patients with MASH and moderate to severe fibrosis.
StrongSupportsmedium confidence
The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was...56% in the 10-mg tirzepatide group (difference, 46 percentage points; P<0.001 for all three comparisons).
Why this rating
Based on a phase 2, randomized, placebo-controlled trial design.
Source
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
Rohit Loomba et al. · New England Journal of Medicine · 2024
rct · n=190Cited 748×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →